Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc.

FHTXยทNASDAQ

$3.64

+0.55%
HealthcareBiotechnology

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$213.72M
EPS-1.1800
P/E Ratio-3.08
Earnings Date08/04/2026

No Dividend Yield Data

FHTX has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

FHTX has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

FHTX has not reported any net dividends paid values in the available annual periods.

Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. Dividend History

FHTX ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

FHTX Dividend Payment History

FHTX ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
fhtx

Foghorn Therapeutics Inc. Payout Ratio Analysis

FHTX ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-74.28M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.